Epogen

Hospira said it will test Retacrit against Epogen, which is sold by biotech giant

chicagotribune.com - 2010

Lake Forest-based Hospira said it will begin the first phase of trials for a "biosimilar," or a biogeneric, version of brand-name Epogen in patients with renal dysfunction who have anemia.

chicagotribune.com - 2010

Insulin produced this way went on sale in 1982; human growth hormone followed, and within the last few years have come another dozen or so, such as Epogen, which stimulates the production of red blood cells, and Neupogen, which enhances white-cell production.

Splashing In The Gene Pool 2008

Insulin produced this way went on sale in 1982; human growth hormone followed, and within the last few years have come another dozen or so, such as Epogen, which stimulates the production of red blood cells, and Neupogen, which enhances white-cell production.

Splashing In The Gene Pool 2008

In addition, a major secondary endpoint being evaluated is the potential ability of Zerenex to decrease the need for IV-iron and blood cell stimulators (EPO agents such as Epogen and Aranesp) since it is iron based and expected to result in long-term accumulation of the mineral.

SeekingAlpha.com: Home Page 2010

Sales of Amgen's anemia drugs Aranesp and Epogen continued to slide, declining a combined 9 percent to $1.22 billion because of lower demand, primarily for Epogen.

Amgen Buys Cancer Drug Maker AP 2011

In Europe, Hospira already sells generic versions of top-selling drugs Epogen and Neupogen, both made by Amgen.

Biotech Firms Fight Generics Alicia Mundy 2011

Epogen and two similar antianemia biologics cost Medicare more than $2 billion in 2009 for dialysis, according to a Medicare spokeswoman.

Biotech Firms Fight Generics Alicia Mundy 2011

The medicines – Procrit, Aranesp and Epogen – are multibillion dollar sellers because of their ability to boost oxygen-carrying red blood cells, reducing the need for painful blood transfusions.

FDA May Limit Anemia Drug Use For Kidney Disease AP 2010

Investors hope the new products will reinvigorate Amgen's sales growth and help make up for declining sales of Aranesp and Epogen.

Amgen Buys Cancer Drug Maker AP 2011